Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors

논문상세정보

' Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors' 의 참고문헌

  • X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp RL [2004]
  • Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to gamma-radiation
    Song JY [2013]
  • Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas
    Wang P [2011]
  • What goes on must come off: phosphatases gate-crash the DNA damage response
    Lee DH [2011]
  • WIP1 phosphatase at the crossroads of cancer and aging
  • Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma
    Jones C [2014]
  • The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways
    Lu X [2008]
  • The somatic genomic landscape of glioblastoma
    Brennan CW [2013]
  • The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
    Cerami E [2012]
  • The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop
    Lu X [2007]
  • The 2016 world health organization classification of tumors of the central nervous system: a summary
    Louis DN [2016]
  • Revisiting the role of p53 in primary and secondary glioblastomas
    Nagpal J [2006]
  • Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
    Tabouret E [2016]
  • PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression
    Chuman Y [2009]
  • PPM1D is a potential therapeutic target in ovarian clear cell carcinomas
    Tan DS [2009]
  • PPM1D is a potential target for 17q gain in neuroblastoma
  • PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
    Lambros MB [2010]
  • PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
    Lu X [2005]
  • Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers
    Yu E [2007]
  • Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas
    Liang C [2012]
  • Mutational landscape and clonal architecture in grade II and III gliomas
    Suzuki H [2015]
  • Molecular markers in glioma
    Ludwig K [2017]
  • Malignant gliomas in adults
    Wen PY [2008]
  • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    Gao J [2013]
  • Glioma subclassifications and their clinical significance
    Chen R [2017]
  • Genome-wide arraybased comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome
  • Genetic variants and mutations of PPM1D control the response to DNA damage
    Dudgeon C [2013]
  • Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway
    Hu W [2010]
  • Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
    Kleiblova P [2013]
  • Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide
    Wang X [2014]
  • Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
    Zhang L [2014]
  • Deregulation of the TP53/p14ARF tumor suppressor pathway in lowgrade diffuse astrocytomas and its influence on clinical course
    Watanabe T [2003]
  • Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas
  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways
  • Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event
    Lass U [2012]
  • Brain tumors
  • Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets
    Hirasawa A [2003]
  • Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity
    Bulavin DV [2002]
  • All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
  • ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
    Reuss DE [2015]
  • A practical review of prognostic correlations of molecular biomarkers in glioblastoma
    Karsy M [2015]